
==== Front
Aging Clin Exp Res
Aging Clin Exp Res
Aging Clinical and Experimental Research
1594-0667
1720-8319
Springer International Publishing Cham

39172286
2831
10.1007/s40520-024-02831-6
Research
Stress hyperglycemia ratio and its influence on mortality in elderly patients with severe community-acquired pneumonia: a retrospective study
Miao Lei 2
Shen Xiaozhu 1
Du Zhiqiang 2
Liao Jingxian superjingxian@163.com

1
1 https://ror.org/0442rdt85 Department of Geriatrics, The Second People’s Hospital of Lianyungang, Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang, Jiangsu China
2 https://ror.org/0442rdt85 Department of Critical Care Medicine, The Second People’s Hospital of Lianyungang, Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang, Jiangsu China
22 8 2024
22 8 2024
2024
36 1 17510 7 2024
5 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

Community-acquired pneumonia (CAP) is a significant health issue among the elderly, with severe cases (SCAP) having high mortality rates. This study assesses the predictive significance of the stress hyperglycemia ratio (SHR) in elderly SCAP patients and its impact on outcomes in both diabetic and non-diabetic patients.

Methods and materials

This retrospective study included 406 SCAP patients aged 65 or older from the Second People’s Hospital of Lianyungang (January 2020 to December 2023). Data collected included demographics, medical history, vital signs, and lab results. SHR was calculated from initial blood glucose and estimated average glucose (HbA1c). Statistical analyses, including Cox regression and Kaplan-Meier analysis, evaluated SHR’s impact on mortality. Mediation models explored the effects of neutrophil-lymphocyte ratio (NLR) and SHR.

Results

The 28-day mortality rate was 21.67%. Deceased patients had higher age, Charlson Comorbidity Index, procalcitonin, NLR, glucose, and SHR levels compared to survivors (P < 0.05). Both SHR and NLR significantly increased mortality risk, particularly in non-diabetic patients. Combining NLR and SHR improved ROC AUC to 0.898, with 89.80% sensitivity and 81.10% specificity. Kaplan-Meier analysis showed higher cumulative survival for SHR < 1.14, regardless of diabetes status (P < 0.05). NLR mediated 13.02% of the SHR-survival relationship, while SHR mediated 14.06% of the NLR-survival relationship.

Conclusion

Elevated SHR is a significant mortality risk factor in elderly SCAP patients, independent of diabetes status. Stringent glucose control and careful monitoring of SHR may improve outcomes in elderly patients with acute respiratory conditions.

Supplementary Information

The online version contains supplementary material available at 10.1007/s40520-024-02831-6.

Keywords

Elderly
Severe community-acquired pneumonia
Stress hyperglycemia
Prognosis
Science and Technology Project of the Kangda College of Nanjing Medical UniversityKD2023KYJJ078 Lianyungang Aging Health Research ProjectL202308 Science and technology project of Lianyungang Health CommissionQN202210 issue-copyright-statement© Springer Nature Switzerland AG 2024
==== Body
pmcIntroduction

Community-acquired pneumonia (CAP) is a significant health issue among the elderly, with severe cases (SCAP) having mortality rates as high as 25-50% [1]. Elderly individuals often have underlying conditions that weaken their immune systems, increasing susceptibility to CAP and exacerbating disease severity [2]. Therefore, assessing SCAP severity in clinical practice is crucial. Weakened immune systems and reduced physiological reserves make elderly patients especially prone to SCAP complications. Additionally, these patients often exhibit glucose metabolism disorders, leading to increased complications and mortality.

Recent epidemiological data show that SCAP is an increasing concern among the global elderly population. Studies indicate that SCAP incidence in individuals aged 65 and older is 10 to 30 cases per 1,000 people annually [3]. Moreover, the hospitalization rate for SCAP in this population is rising, significantly impacting healthcare utilization. Despite medical advances, the prognosis for elderly SCAP patients remains poor, highlighting the need for improved diagnostic and treatment strategies.

Stress hyperglycemia is commonly observed in patients with acute illnesses, often due to infections and neuroendocrine disorders [4–6]. Numerous studies have explored the association between the stress hyperglycemia ratio (SHR) and adverse outcomes, such as mortality, length of hospital stay, and complications, emphasizing SHR’s potential utility as a simple and easily obtainable biomarker [7–9]. Patients with severe pneumonia often experience blood glucose fluctuations and develop stress hyperglycemia due to limited oxygen supply [4, 5]. To better evaluate this, SHR combines the initial blood glucose level with an estimated average derived from glycated hemoglobin (HbA1c) [10]. This novel index accounts for baseline glucose levels by utilizing HbA1c, reflecting long-term glycemic control unaffected by acute exacerbations [11].

The relevance of diabetes in the context of SHR and its potential impact on SCAP prognosis is worthy of in-depth study. Diabetic patients, due to long-term hyperglycemia, may respond differently to stress, affecting disease progression and prognosis. Diabetes alters the body’s response to infections and exacerbates the condition through mechanisms like increased inflammatory responses and oxidative stress [12–14]. Studying SHR differences and prognosis between diabetic and non-diabetic SCAP patients is crucial for developing personalized treatment strategies.

This study aims to assess SHR’s predictive significance in elderly SCAP patients and explore its impact on adverse outcomes in both diabetic and non-diabetic patients. By filling this research gap, we hope to provide targeted management strategies to potentially improve outcomes in this vulnerable population.

Methods

Study design and patients

The retrospective study was conducted at the Department of Geriatrics, the Second People’s Hospital of Lianyungang affiliated with Kangda College of Nanjing Medical University, from January 2020 to December 2023. Patients aged 65 years or older with a minimum hospital stay of 2 days and meeting the SCAP diagnostic criteria by the Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) were included [15]. Exclusion criteria were: death within 24 h of admission, hospitalization exceeding 60 days, long-term use of immunosuppressive agents or glucocorticoids, history of acquired immunodeficiency or organ transplantation, undergoing chemoradiotherapy for cancer or hematologic cancer treatment, experiencing diabetic emergencies, or having hospital-acquired infections. The study was approved by the Ethics Committee of the Second People’s Hospital of Lianyungang (NO.2022K040), which waived the requirement for informed consent due to the study’s retrospective, non-interventional, and non-intrusive nature.

Data collection

Researchers trained in using electronic medical record systems collected comprehensive clinical data. This included timestamps of patient admission and discharge, as well as demographic and medical information such as gender, age, contact details, past medical history, underlying diseases, and vital signs upon admission (temperature, heart rate, respiration rate, blood pressure). Within 24 h of admission, the Charlson Comorbidity Index (CCI) was calculated to assess the presence and severity of comorbidities. CCI calculation involved assigning weighted scores to 19 different medical conditions, with scores ranging from 1 to 6, and summing the assigned scores to obtain an overall index [16].

The Oxygenation Index (OI) was determined using the formula: OI = PaO2/FiO2, where PaO₂ is the arterial partial oxygen pressure and FiO₂ is the inhaled oxygen concentration, providing insights into the patients’ respiratory status [17]. Laboratory tests were performed within the first 24 h of admission, measuring hemoglobin (HB), platelet count (PLT), white blood cell count (WBC), aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), serum creatinine (Scr), serum uric acid (SUA), serum albumin (ALB), procalcitonin (PCT), hypersensitive C-reactive protein (hs-CRP), blood glucose (Glu), and glycosylated hemoglobin (HbA1c). The neutrophil-lymphocyte ratio (NLR) was calculated based on neutrophil and lymphocyte counts.

Definition and outcome

The stress hyperglycemia ratio (SHR) was calculated based on HbA1c, representing the blood glucose level upon admission divided by the estimated mean blood glucose. The formula is: SHR = Admission Glucose Level / Estimated Average Glucose Level from HbA1c. The calculation of the estimated average glucose level from HbA1c is based on the widely accepted formula: Estimated Average Glucose (mg/dL) = 28.7×HbA1c (%) − 46.7 [10]. In this study, the admission glucose level was defined as the initial plasma glucose concentration within 24 h of admission.

Patients were classified into survival and death groups based on a 28-day follow-up. A comparison was made between the two groups regarding clinical characteristics and SHR levels. Additionally, the impact of SHR on mortality was compared in elderly SCAP patients with and without diabetes. Diabetes was defined as prior treatment with insulin or oral hypoglycemic agents or previously undiagnosed diabetes with HbA1c ≥ 6.5% upon admission.

Statistical analysis

Statistical analyses were conducted using IBM SPSS Statistics version 21 and PROCESS 4.1. For categorical data, the Chi-squared test was used for group comparisons. The Student t-test was applied to continuous data with normal distribution, expressed as mean ± standard deviation. For quantitative data not conforming to a normal distribution, the non-parametric Mann-Whitney U test was used, expressed as median (quartile) [M (Q1, Q3)]. The Cox proportional hazards regression model was used to evaluate the relationship between the SHR, NLR, and adverse outcomes in SCAP patients. Receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) were calculated to assess the predictive value of SHR, NLR, and their combined detection. Patients were categorized into two groups based on the cut-off value of SHR. The cut-off value for SHR was determined using ROC curve analysis. Specifically, we used ROC curve analysis to assess the predictive value of SHR for adverse outcomes and selected the cut-off value that maximized sensitivity and specificity. Kaplan-Meier survival analysis was conducted to evaluate the impact of SHR on survival outcomes in patients with or without diabetes, and a log-rank test was used to determine if there was a statistically significant difference in survival between these groups. Using the Bootstrap approach, 5000 repeated samples were analyzed to assess the mediating effect of NLR and SHR. The mediating effect was considered statistically significant if the 95% confidence interval did not include zero. All statistical tests were two-sided, with a significance level set at P < 0.05.

Results

Patient characteristics

The study enrolled a cohort of 406 elderly patients diagnosed with SCAP, adhering to specific inclusion and exclusion criteria as outlined in Fig. 1. The participants had an average age of 80.30 ± 5.26 years, with a 28-day mortality rate of 21.67%. Comparative analysis revealed that the deceased group exhibited significantly higher levels of age, CCI score, PCT, NLR, Glu, and SHR compared to the surviving group ( P < 0.05). No significant differences were observed between the two groups regarding gender distribution, prevalence of comorbidities (such as hypertension, diabetes, coronary heart disease, chronic kidney disease, cerebrovascular disease, and chronic lung disease), or etiology ( P > 0.05). Additionally, there were no statistically significant differences in various laboratory and clinical parameters, including AST, ALT, Scr, SUA, WBC, PLT, HB, ALB, hs-CRP, HbA1c, HR, SBP, DBP, and OI between the two groups ( P > 0.05, Table 1).

Fig. 1 Flow diagram displaying the progress of all participants through the study

Table 1 Baseline characteristics of elderly SCAP patients in both groups

Variables	Total (n = 406)	Survival group(n = 318)	Death group(n = 88)	P	
Male, n (%)	234(57.64)	181(56.92)	53(60.23)	0.627	
Age, mean (SD)	80.30(5.26)	80.83(5.15)	83.00(5.31)	0.001	
Underlying diseases					
Hypertension, n (%)	195(48.03)	147(46.23)	48(54.55)	0.186	
Diabetes, n (%)	152(37.44)	114(35.85)	38(43.18)	0.216	
Coronary heart disease, n (%)	136(33.50)	101(31.76)	35(39.77)	0.163	
Chronic kidney disease, n (%)	111(27.34)	83(26.10)	28(31.82)	0.283	
Cerebrovascular disease, n (%)	132(32.51)	100(31.45)	32(36.36)	0.441	
Chronic lung disease, n (%)	135(33.25)	104(32.70)	31(35.23)	0.702	
Etiology					
Influenza virus, n (%)	81(19.96)	63(19.81)	18(20.45)	0.881	
COVID-19, n (%)	67(16.50)	48(15.09)	19(21.59)	0.148	
Bacterial pneumonia, n (%)	147(36.21)	110(34.59)	37(42.05)	0.211	
CCI, mean (SD)	2.99(1.20)	2.76(1.10)	3.81(1.17)	< 0.001	
AST, U/L, median (IQR)	26.00(22.00,38.00)	26.00(22.00,39.00)	26.00(22.00,35.00)	0.800	
ALT, U/L, median (IQR)	23.00(17.00,33.00)	22.00(17.75,33.00)	24.00(17.00,37.00)	0.795	
BUN, mmol/L, median (IQR)	7.50(5.98,10.30)	7.30(5.70,10.20)	8.20(6.90,11.85)	0.016	
Scr,µmmol/L, median (IQR)	78.50(63.00,117.00)	77.00(63.00,115.00)	86.00(65.50,124.00)	0.106	
SUA,µmmol/L, median (IQR)	259.50(202.00,340.00)	257.00(202.00,324.00)	293.00(191.00,363.75)	0.265	
WBC, ×109L, mean (SD)	13.01(3.99)	12.88(3.93)	13.48(4.17)	0.212	
NLR, median (IQR)	9.93(6.45,13.83)	8.07(6.22,12.38)	19.06(12.74,24.86)	< 0.001	
PLT, ×109L, median (IQR)	158.00(125.00,209.00)	157.00(129.00,209.00)	183.00(119.00,210.00)	0.954	
HB, g/L, mean (SD)	101.52(22.20)	100.64(22.91)	104.69(19.22)	0.130	
PCT, ng/ml, median (IQR)	3.25(1.40,6.49)	2.77(1.21,6.18)	5.10(2.23,10.38)	< 0.001	
ALB, g/L, mean (SD)	31.58(3.97)	31.42(3.98)	32.18(3.91)	0.109	
hs-CRP, mg/L, median (IQR)	110.00(44.40,162.00)	91.30(44.13,164.70)	121.00(55.40,162.00)	0.491	
Glu, mmol/L, median (IQR)	7.90(6.55,10.58)	7.68(6.50,10.47)	8.50(7.70,11.93)	< 0.001	
HbA1c,%,median (IQR)	5.86(5.50,7.70)	5.82(5.50,7.70)	6.25(5.43,7.80)	0.620	
SHR, median (IQR)	1.12(1.04,1.20)	1.10(1.03,1.15)	1.21(1.15,1.30)	< 0.001	
HR, beats/min, median (IQR)	95.00(81.00,111.25)	96.00(78.00,112.00)	95.00(88.25,111.00)	0.432	
SBP, mmHg, median (IQR)	129.00(105.00,145.00)	128.00(104.00,145.00)	129.00(109.00,144.00)	0.441	
DBP, mmHg, median (IQR)	73.00(62.00,86.00)	73.00(62.00,86.00)	70.50(63.50,84.00)	0.370	
OI, mmHg, median (IQR)	316.67(296.67,324.17)	316.67(300.00,323.33)	310.00(296.67,326.67)	0.224	
Abbreviations COVID-19, coronavirus disease 2019; CCI, Charlson Comorbidity Index, AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, Blood urea nitrogen; Scr, Serum creatinine; SUA, Serum uric acid, Hb Hemoglobin; PLT, Platelet count; WBC, White blood cell count; PCT, Procalcitonin; NLR, Neutrophil lymphocyte ratio; hs-CRP, Hypersensitive C-reactive protein; ALB, Serum albumin; Glu, plasma glucose; HbA1c, Glycosylated hemoglobin; SHR, Stress hyperglycemia ratio; HR, Heart rate at admission; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; OI, Oxygenation Index; SD, Standard deviation; IQR, Interquartile range

Cox proportional hazards regression results

The Cox proportional hazards regression model was used to evaluate the relationship between SHR, NLR, and adverse outcomes in SCAP patients. Three models were employed to understand these relationships across different levels of adjustments for covariates. Model 1: No covariates were adjusted. Model 2: Adjusted for sex, age and CCI. Model 3: Adjusted for age, sex, CCI, underlying diseases, etiology, AST, ALT, BUN, Scr, SUA, WBC, PLT, HB, ALB, hs-CRP, and PCT. Table 2 shows the detailed results and interpretations from each model for both diabetic (DM) and non-diabetic (Non-DM) groups. NLR is significantly associated with increased mortality risk in diabetic patients across all models. For each unit increase in NLR, the risk of mortality increases by approximately 9.1% (Model 1), 9.8% (Model 2), and 15.0% (Model 3), all highly significant with P < 0.001. SHR is also significantly associated with increased mortality risk in diabetic patients. For each unit increase in SHR, the risk of mortality increases by approximately 297% (Model 1), 264.6% (Model 2), and 480.3% (Model 3), with consistently significant P-values (P < 0.001). NLR is significantly related to increased mortality risk in non-diabetic patients, though the effect is slightly weaker than in diabetic patients. For each unit increase in NLR, the risk of mortality increases by approximately 7.7% (Model 1), 6.3% (Model 2), and 6.1% (Model 3), all statistically significant. SHR is highly predictive of mortality risk in non-diabetic patients. For each unit increase in SHR, the risk of mortality increases dramatically by approximately 1063% (Model 1), 813% (Model 2), and 1006% (Model 3), all with P-values well below 0.001.

Table 2 Cox proportional hazards regression results in defferent models

		Model 1 (HR, 95%CI)	P	Model 2 (HR, 95%CI)	P	Model 3 (HR, 95%CI)	P	
DM-Group	NLR	1.091 (1.066, 1.117)	< 0.001	1.098 (1.066, 1.131)	< 0.001	1.150 (1.091, 1.211)	< 0.001	
SHR	3.972 (1.725, 9.147)	0.001	3.646 (1.456, 9.133)	0.006	5.803 (1.736, 19.397)	0.004	
Non-DM Group	NLR	1.077 (1.043, 1.113)	< 0.001	1.063 (1.025, 1.102)	0.001	1.061 (1.017, 1.107)	0.007	
SHR	11.637 (5.440, 24.891)	< 0.001	9.130 (4.144, 20.114)	< 0.001	11.063 (4.653, 26.300)	< 0.001	
Model 1: we did not adjust other covariates

Model 2: we adjust sex, age and CCI

Model 3: we adjust age, sex, CCI, underlying diseases, etiology, AST, ALT, BUN, Scr, SUA, WBC, PLT, HB, ALB, hs-CRP, and PCT

Abbreviations CCI, Charlson Comorbidity Index, AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, Blood urea nitrogen; Scr, Serum creatinine; SUA, Serum uric acid, Hb Hemoglobin; PLT, Platelet count; WBC, White blood cell count; PCT, Procalcitonin; NLR, Neutrophil lymphocyte ratio; hs-CRP, Hypersensitive C-reactive protein; ALB, Serum albumin; SHR, Stress hyperglycemia ratio; HR, Hazard Ratio; CI, Confidence Interval

Prognostic value of shr and combined detection

Receiver operating characteristic (ROC) curve analysis was conducted to evaluate the predictive value of NLR, SHR, and their combination for adverse outcomes in elderly patients with SCAP. For SHR, the determined cut-off value was 1.14, which achieved the best balance between sensitivity and specificity. The AUC was 0.818 (95% CI: 0.776–0.870) for NLR and 0.823(95% CI: 0.778–0.869) for SHR. For NLR, a cut-off value of 13.28 yielded 73.90% sensitivity and 83.30% specificity. For SHR, a cut-off value of 1.14 resulted in 83.00% sensitivity and 71.10% specificity. Combining NLR and SHR increased the AUC to 0.898 (95% CI: 0.860–0 0.936), providing 89.80% sensitivity and 81.10% specificity ( Fig. 2).

Fig. 2 ROC curve of the predictive value Abbreviations NLR, Neutrophil lymphocyte ratio; SHR, Stress hyperglycemia ratio

Kaplan-Meier survival analysis

Among 254 non-diabetic patients, the group with SHR < 1.14 had 8 deaths out of 169 patients, with a survival time of 27.25 ± 0.26 days and a cumulative survival rate of 95.27%. Conversely, in the group with SHR ≥ 1.14, there were 42 deaths out of 85 patients, with a survival time of 20.88 ± 0.86 days and a cumulative survival rate of 50.59%. For 152 diabetic patients, the group with SHR < 1.14 had 7 deaths out of 71 patients, with an average survival time of 26.54 ± 0.56 days and a cumulative survival rate of 90.14%. In the group with SHR ≥ 1.14, 31 deaths were observed among 81 patients, with an average survival time of 22.38 ± 0.88 days and a cumulative survival rate of 61.73%. A statistically significant difference in cumulative survival was observed between these groups (Log-Rank test: χ² = 90.038, P < 0.001) (Fig. 3).

Fig. 3 Kaplan-Meier survival curve Abbreviations SHR, stress hyperglycemia ratio; DM, diabetes mellitus

Simple mediational analyses

A simple mediational model, adjusted for all potential confounders, showed that NLR mediated the relationship between SHR and survival with an indirect effect of 1.831 (95% CI: 0.600–3.471), accounting for 13.02% of the total effect. Similarly, SHR mediated the relationship between NLR and survival with an indirect effect of 0.027 (95%CI: 0.010–0.051), accounting for 14.06% of the total effect (Supplementary Fig. 1). This suggests that NLR and SHR not only independently serve as predictors but also interact with each other.

Discussion

Community-acquired pneumonia (CAP), particularly its severe form (SCAP), presents a major public health challenge among the elderly due to a combination of factors such as aspiration risk, weakened immune responses, compromised lung function, and pulmonary microangiopathy [2, 18]. Factors that increase susceptibility to infection or exacerbate disease severity significantly impact clinical outcomes. Emerging evidence links stress hyperglycemia, characterized by elevated blood glucose levels, with impaired immune function, and the degree of glycemic disruption reflects the severity of the underlying illness [19, 20]. Stress hyperglycemia can impair lung function, reduce oxygenation capacity, and hinder infection control, leading to prolonged hospital stays and increased mortality [6]. Our study supports this evidence, demonstrating significantly higher initial glucose concentrations in deceased patients compared to survivors.

In recent years, SHR has become a recognized indicator of stress hyperglycemia, accounting for both pre-hospital and post-hospital glucose levels. Studies have established that elevated SHR is associated with adverse outcomes in cardiovascular and cerebrovascular diseases, including higher mortality, longer hospital stays, and increased nosocomial infections [21–23]. Mohammed AQ et al. found that elevated SHR was independently associated with hospitalization for all-cause death, cardiovascular death, and readmission for heart failure [24]. Xu W et al. showed a correlation between SHR and in-hospital mortality in coronary heart disease patients, indicating an SHR index greater than 1.20 increased the risk, especially in pre-diabetes and diabetes mellitus patients [25]. Furthermore, elevated SHR is linked to increased morbidity and mortality following acute myocardial infarction (AMI) [26], and is a predictor for acute kidney injury (AKI), all-cause death, and cardiogenic shock post-AMI [27]. In acute coronary syndrome (ACS) patients, high SHR suggests a higher risk of short-term and long-term adverse outcomes [28]. Our study fills a gap by exploring the relationship between SHR and prognosis in elderly SCAP patients. We reveal significantly higher SHR levels in the deceased group, identifying SHR as a critical mortality risk factor regardless of diabetes mellitus status. This suggests SHR can be a key prognostic indicator for elderly SCAP patients.

This study, through multivariate Cox regression analysis, clearly establishes the clinical significance of the SHR and the NLR as independent prognostic factors in patients with SCAP. Regardless of whether covariates were adjusted, both SHR and NLR significantly increased the risk of mortality. NLR is a significant predictor of mortality in both diabetic and non-diabetic groups. However, the impact appears somewhat stronger in diabetic patients when considering the hazard ratios. SHR exhibits a markedly higher impact on mortality risk, especially in non-diabetic patients. The hazard ratios for SHR are significantly higher in non-diabetic patients across all models, suggesting that SHR plays a crucial role in predicting mortality in this group. Adjusting for additional covariates (from Model 1 to Model 3) generally increases the hazard ratios, which might indicate the presence of confounding factors that attenuate the apparent relationships in unadjusted analyses.These results suggest the need for close monitoring and potential interventional strategies targeting SHR and NLR levels, especially in non-diabetic SCAP patients, to improve clinical outcomes.

Our findings align with Liu B et al., who reported that high SHR in pneumonia patients was associated with increased inflammatory markers, including white blood cells, NLR, C-reactive protein, PCT, and erythrocyte sedimentation rate (ESR) [29]. Consistent with these observations, our study found elevated NLR and PCT levels in deceased patients. Chronic inflammation plays a crucial role in the initiation and progression of diabetes, and chronic hyperglycemia itself can contribute to increased oxidative stress and further stimulate inflammation. Tao J et al. found a strong correlation between elevated SHR levels and an increased risk of stroke-related pneumonia (SAP), particularly among non-diabetic patients [30]. Our study also revealed that SHR and NLR are not only independent prognostic factors but also exhibit interactions with each other. A simple mediation analysis indicated that NLR acts as a mediator in the relationship between SHR and survival, and vice versa. NLR and SHR not only independently serve as prognostic indicators for SCAP patients but also interact with each other. This finding underscores the complex relationship between inflammation and stress responses in critically ill patients. NLR is a crucial indicator of systemic inflammatory response. A high NLR typically indicates a more robust inflammatory reaction, which may influence the overall prognosis of the patients [31]. SHR reflects the hyperglycemic state of the body under stress. Stress hyperglycemia can be driven by multiple factors, including hormone release (such as cortisol and adrenaline) and increased insulin resistance [32]. The interaction between NLR and SHR might reflect the interplay between inflammatory and stress responses in critically ill patients. A high NLR might exacerbate hyperglycemic states and vice versa, potentially worsening the prognosis.

Addressing stress hyperglycemia requires recognizing the complex interaction between comorbidities, inflammation, and glucose dysregulation. Tailored therapeutic strategies to optimize glycemic control may reduce complications and improve outcomes in elderly patients with SCAP. Investing in the development and implementation of management strategies addressing stress hyperglycemia in community-acquired pneumonia could significantly reduce its public health burden, enhance patient outcomes, and improve healthcare efficiency.

In this study, we used the admission blood glucose level to calculate SHR, aligning with the standard methodology used in existing literature. However, it is important to note that blood glucose levels can fluctuate significantly during hospitalization, which may impact patient outcomes. Therefore, examining SHR at multiple time points during hospitalization could offer a more comprehensive and dynamic perspective on hyperglycemia. Specifically, future research could consider calculating SHR at both the initial and final stages of admission to compare their impacts on mortality and other clinical outcomes. This approach could reveal the dynamic changes in stress hyperglycemia throughout the course of the illness and help identify high-risk patient groups, thereby improving clinical intervention strategies. For instance, further studies could explore whether continuous glucose monitoring during hospitalization can more accurately predict patient prognosis and inform personalized treatment plans.

Looking forward, future research directions should focus on the development of personalized treatment protocols aimed at better managing stress hyperglycemia in elderly patients with CAP. Additionally, investigating the molecular mechanisms underlying the relationship between hyperglycemia and immune response could unlock new therapeutic targets. The integration of artificial intelligence and machine learning to predict patient outcomes based on SHR and other biomarkers may also provide a more precise approach to managing and ultimately improving the prognosis of elderly patients with SCAP.

This retrospective study, conducted at a single center with a limited sample size, offers valuable insights into the impact of the stress hyperglycemia ratio (SHR) on the prognosis of patients with community-acquired pneumonia (CAP). However, the study’s design presents several limitations. The single-center nature of the study may limit the generalizability of the findings to broader populations. Additionally, the relatively small sample size restricts the statistical power and the ability to detect more subtle effects. The lack of etiological classification of CAP in our study is another limitation, as the influence of different pathogens on the observed outcomes remains unclear. Potential selection bias also exists, as the study population may not be fully representative of all elderly patients with CAP.

To address these limitations, future large-scale, multicenter prospective studies are necessary to validate and expand upon our findings. Such studies should aim to include a more diverse patient population and provide a detailed etiological classification of CAP. Furthermore, exploring other indicators of blood glucose variation, such as time in target blood glucose range and glucose variability, could provide a more comprehensive understanding of glycemic control’s impact on long-term outcomes and quality of life in critically ill elderly patients.

Conclusions

This study highlights that an increased SHR is a significant risk factor for mortality in elderly patients with SCAP, irrespective of the presence of diabetes. The pivotal impact of SHR on clinical outcomes underscores its importance as a potentially modifiable risk factor. Managing SHR levels through stringent glucose control and meticulous monitoring may lead to an improved prognosis for elderly patients with acute respiratory conditions.

These findings emphasize the need for a comprehensive approach to patient care, where clinicians must closely monitor and manage SHR levels alongside other clinical parameters to optimize treatment strategies. By integrating SHR management into routine clinical practice, healthcare providers can enhance the overall survival and well-being of the elderly SCAP population. Future research should focus on developing tailored therapeutic protocols and investigating the underlying mechanisms linking hyperglycemia and immune response. Additionally, the potential of advanced predictive analytics, such as artificial intelligence and machine learning, in optimizing glycemic control and improving patient outcomes warrants further exploration.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1: Simple mediational analyses Abbreviations NLR, Neutrophil lymphocyte ratio; SHR, Stress hyperglycemia ratio.

Author contributions

Lei Miao: Writing – original draft, Data curation, Funding acquisition. Xiaozhu Shen: Supervision, Resources. Zhiqiang Du: Supervision, Resources. Jingxian Liao: Writing – review & editing, Writing – original draft, Funding acquisition, Formal analysis, Data curation, Conceptualization.

Funding

This work was supported by Lianyungang Aging Health Research Project (L202308), Science and technology project of Lianyungang Health Commission (QN202210), and Science and Technology Project of the Kangda College of Nanjing Medical University (KD2023KYJJ078).

Data availability

All the data will be available from the corresponding author upon reasonable request.

Declarations

Ethical approval

This study was approved by the Ethics Committee of the Second People’s Hospital of Lianyungang (NO. 2022K040 ). The Ethical Committee waived the requirement for informed consent since this study was retrospective, non-interventional and non- intrusive.

Competing interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Jain S Self WH Wunderink RG Community-acquired pneumonia requiring hospitalization among US adults N Engl J Med 2015 373 5 415 427 10.1056/NEJMoa1500245 26172429
Jain S, Self WH, Wunderink RG et al (2015) Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med 373(5):415–427. 10.1056/NEJMoa150024526172429 10.1056/NEJMoa1500245
2. Torres A Chalmers JD Dela Cruz CS Challenges in severe community-acquired pneumonia:a point-of-view review Intensive Care Med 2019 45 159 171 10.1007/s00134-019-05519-y 30706119
Torres A, Chalmers JD, Dela Cruz CS et al (2019) Challenges in severe community-acquired pneumonia:a point-of-view review. Intensive Care Med 45:159–171. 10.1007/s00134-019-05519-y30706119 10.1007/s00134-019-05519-y
3. Tsoumani E Carter JA Salomonsson S Clinical, economic, and humanistic burden of community acquired pneumonia in Europe:a systematic literature review Expert Rev Vaccines 2023 22 1 876 884 10.1080/14760584.2023.2261785 37823894
Tsoumani E, Carter JA, Salomonsson S et al (2023) Clinical, economic, and humanistic burden of community acquired pneumonia in Europe:a systematic literature review. Expert Rev Vaccines 22(1):876–884. 10.1080/14760584.2023.226178537823894 10.1080/14760584.2023.2261785
4. Dungan KM Braithwaite SS Preiser JC Stress hyperglycaemia Lancet 2009 373 1798 1807 10.1016/S0140-6736(09)60553-5 19465235
Dungan KM, Braithwaite SS, Preiser JC (2009) Stress hyperglycaemia. Lancet 373:1798–1807. 10.1016/S0140-6736(09)60553-519465235 10.1016/S0140-6736(09)60553-5
5. Lee TF Drake SM Roberts GW Relative hyperglycemia is an independent determinant of in-hospital mortality in patients with critical illness Crit Care Med 2020 48 2 e115 e122 10.1097/CCM.0000000000004133 31939810
Lee TF, Drake SM, Roberts GW et al (2020) Relative hyperglycemia is an independent determinant of in-hospital mortality in patients with critical illness. Crit Care Med 48(2):e115–e122. 10.1097/CCM.000000000000413331939810 10.1097/CCM.0000000000004133
6. Marik PE Bellomo R Stress hyperglycemia: an essential survival response! Crit Care 2013 17 1 7 10.1186/cc12514
Marik PE, Bellomo R (2013) Stress hyperglycemia: an essential survival response! Crit Care 17:1–7. 10.1186/cc1251410.1186/cc12514
7. Abdu FA Galip J Qi P Association of stress hyperglycemia ratio and poor long-term prognosis in patients with myocardial infarction with non-obstructive coronary arteries Cardiovasc Diabetol 2023 22 1 1 11 10.1186/s12933-023-01742-6 36609317
Abdu FA, Galip J, Qi P et al (2023) Association of stress hyperglycemia ratio and poor long-term prognosis in patients with myocardial infarction with non-obstructive coronary arteries. Cardiovasc Diabetol 22(1):1–11. 10.1186/s12933-023-01742-636609317 10.1186/s12933-023-01742-6
8. Liu J Zhou Y Huang H Impact of stress hyperglycemia ratio on mortality in patients with critical acute myocardial infarction: insight from American MIMIC-IV and the Chinese CIN-II study Cardiovasc Diabetol 2023 22 1 281 10.1186/s12933-023-02012-1 37865764
Liu J, Zhou Y, Huang H et al (2023) Impact of stress hyperglycemia ratio on mortality in patients with critical acute myocardial infarction: insight from American MIMIC-IV and the Chinese CIN-II study. Cardiovasc Diabetol 22(1):281. 10.1186/s12933-023-02012-137865764 10.1186/s12933-023-02012-1
9. Mondal S DasGupta R Lodh M Stress hyperglycemia ratio, rather than admission blood glucose, predicts in-hospital mortality and adverse outcomes in moderate-to severe COVID-19 patients, irrespective of pre-existing glycemic status Diabetes Res Clin Pract 2022 190 109974 10.1016/j.diabres.2022.109974 35809688
Mondal S, DasGupta R, Lodh M et al (2022) Stress hyperglycemia ratio, rather than admission blood glucose, predicts in-hospital mortality and adverse outcomes in moderate-to severe COVID-19 patients, irrespective of pre-existing glycemic status. Diabetes Res Clin Pract 190:109974. 10.1016/j.diabres.2022.10997435809688 10.1016/j.diabres.2022.109974
10. Roberts GW Quinn SJ Valentine N Relative hyperglycemia, a marker of critical illness: introducing the stress hyperglycemia ratio J Clin Endocrinol Metab 2015 100 12 4490 4497 10.1210/jc.2015-2660 26485219
Roberts GW, Quinn SJ, Valentine N et al (2015) Relative hyperglycemia, a marker of critical illness: introducing the stress hyperglycemia ratio. J Clin Endocrinol Metab 100(12):4490–4497. 10.1210/jc.2015-266026485219 10.1210/jc.2015-2660
11. Nathan DM Turgeon H Regan S Relationship between glycated haemoglobin levels and mean glucose levels over time Diabetologia 2007 50 2239 2244 10.1007/s00125-007-0803-0 17851648
Nathan DM, Turgeon H, Regan S (2007) Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 50:2239–2244. 10.1007/s00125-007-0803-017851648 10.1007/s00125-007-0803-0
12. Krinsley JS Rule P Pappy L The interaction of acute and chronic glycemia on the relationship of hyperglycemia, hypoglycemia, and glucose variability to mortality in the critically ill Crit Care Med 2020 48 12 1744 1751 10.1097/CCM.0000000000004599 33031146
Krinsley JS, Rule P, Pappy L et al (2020) The interaction of acute and chronic glycemia on the relationship of hyperglycemia, hypoglycemia, and glucose variability to mortality in the critically ill. Crit Care Med 48(12):1744–1751. 10.1097/CCM.000000000000459933031146 10.1097/CCM.0000000000004599
13. Schmitz T Freuer D Harmel E Prognostic value of stress hyperglycemia ratio on short-and long-term mortality after acute myocardial infarction Acta Diabetol 2022 59 8 1019 1029 10.1007/s00592-022-01893-0 35532812
Schmitz T, Freuer D, Harmel E et al (2022) Prognostic value of stress hyperglycemia ratio on short-and long-term mortality after acute myocardial infarction. Acta Diabetol 59(8):1019–1029. 10.1007/s00592-022-01893-035532812 10.1007/s00592-022-01893-0
14. Tian Y Wang R Zhang M Stress-induced hyperglycemia ratio as an independent risk factor of In-hospital mortality in Nonresuscitation Intensive Care units: a retrospective study Clin Ther 2023 3 1 31 39 10.1016/j.clinthera.2022.12.007
Tian Y, Wang R, Zhang M et al (2023) Stress-induced hyperglycemia ratio as an independent risk factor of In-hospital mortality in Nonresuscitation Intensive Care units: a retrospective study. Clin Ther 3(1):31–39. 10.1016/j.clinthera.2022.12.00710.1016/j.clinthera.2022.12.007
15. Metlay JP Waterer GW Long AC Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America Am J Respir Crit Care Med 2019 200 7 e45 e67 10.1164/rccm.201908-1581ST 31573350
Metlay JP, Waterer GW, Long AC et al (2019) Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 200(7):e45–e67. 10.1164/rccm.201908-1581ST31573350 10.1164/rccm.201908-1581ST
16. Ternavasio-De La Vega HG Castaño-Romero F Ragozzino S The updated Charlson comorbidity index is a useful predictor of mortality in patients with Staphylococcus aureus bacteraemia Epidemiol Infect 2018 146 16 2122 2130 10.1017/S0950268818002480 30173679
Ternavasio-De La Vega HG, Castaño-Romero F, Ragozzino S et al (2018) The updated Charlson comorbidity index is a useful predictor of mortality in patients with Staphylococcus aureus bacteraemia. Epidemiol Infect 146(16):2122–2130. 10.1017/S095026881800248030173679 10.1017/S0950268818002480
17. Shen Y Zhu L Yan J Stability of Spo2/Fio2 and respiratory rate-oxygenation indexes in critical respiratory disorders Crit Care Med 2022 50 8 e694 e695 10.1097/CCM.0000000000005559 35838269
Shen Y, Zhu L, Yan J (2022) Stability of Spo2/Fio2 and respiratory rate-oxygenation indexes in critical respiratory disorders. Crit Care Med 50(8):e694–e695. 10.1097/CCM.000000000000555935838269 10.1097/CCM.0000000000005559
18. Faverio P Aliberti S Bellelli G The management of community-acquired pneumonia in the elderly Eur J Intern Med 2014 25 4 312 319 10.1016/j.ejim.2013.12.001 24360244
Faverio P, Aliberti S, Bellelli G et al (2014) The management of community-acquired pneumonia in the elderly. Eur J Intern Med 25(4):312–319. 10.1016/j.ejim.2013.12.00124360244 10.1016/j.ejim.2013.12.001
19. Aon M Alsaeedi A Alzafiri A Stress hyperglycemia ratio as a prognostic marker in diabetic patients hospitalized with COVID-19 Infect Dis Rep 2022 14 5 675 685 10.3390/idr14050073 36136823
Aon M, Alsaeedi A, Alzafiri A et al (2022) Stress hyperglycemia ratio as a prognostic marker in diabetic patients hospitalized with COVID-19. Infect Dis Rep 14(5):675–685. 10.3390/idr1405007336136823 10.3390/idr14050073
20. Huang YW An YH Yin XS Association of the stress hyperglycemia ratio and clinical outcomes in patients with cardiovascular diseases: a systematic review and meta-analysis Eur Rev Med Pharmacol Sci 2022 26 24 9258 9269 10.26355/eurrev_202212_30679 36591838
Huang YW, An YH, Yin XS et al (2022) Association of the stress hyperglycemia ratio and clinical outcomes in patients with cardiovascular diseases: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 26(24):9258–9269. 10.26355/eurrev_202212_3067936591838 10.26355/eurrev_202212_30679
21. Yang J Zheng Y Li C The impact of the stress hyperglycemia ratio on short-term and long-term poor prognosis in patients with acute coronary syndrome: insight from a large cohort study in Asia Diabetes Care 2022 45 4 947 956 10.2337/dc21-1526 35045167
Yang J, Zheng Y, Li C et al (2022) The impact of the stress hyperglycemia ratio on short-term and long-term poor prognosis in patients with acute coronary syndrome: insight from a large cohort study in Asia. Diabetes Care 45(4):947–956. 10.2337/dc21-152635045167 10.2337/dc21-1526
22. Zhou Q Yang J Wang W The impact of the stress hyperglycemia ratio on mortality and rehospitalization rate in patients with acute decompensated heart failure and diabetes Cardiovasc Diabetol 2023 22 1 189 10.1186/s12933-023-01908-2 37495967
Zhou Q, Yang J, Wang W et al (2023) The impact of the stress hyperglycemia ratio on mortality and rehospitalization rate in patients with acute decompensated heart failure and diabetes. Cardiovasc Diabetol 22(1):189. 10.1186/s12933-023-01908-237495967 10.1186/s12933-023-01908-2
23. Zhang C Shen HC Liang WR Relationship between stress hyperglycemia ratio and allcause mortality in critically ill patients: results from the MIMIC-IV database Front Endocrinol (Lausanne) 2023 14 1111026 10.3389/fendo.2023.1111026 37077351
Zhang C, Shen HC, Liang WR et al (2023) Relationship between stress hyperglycemia ratio and allcause mortality in critically ill patients: results from the MIMIC-IV database. Front Endocrinol (Lausanne) 14:1111026. 10.3389/fendo.2023.111102637077351 10.3389/fendo.2023.1111026
24. Mohammed AQ Luo Y Wang K Stress hyperglycemia ratio as a prognostic indicator for long-term adverse outcomes in heart failure with preserved ejection fraction Cardiovasc Diabetol 2024 23 1 1 11 10.1186/s12933-024-02157-7 38172989
Mohammed AQ, Luo Y, Wang K et al (2024) Stress hyperglycemia ratio as a prognostic indicator for long-term adverse outcomes in heart failure with preserved ejection fraction. Cardiovasc Diabetol 23(1):1–11. 10.1186/s12933-024-02157-738172989 10.1186/s12933-024-02157-7
25. Xu W Song Q Wang X Association of stress hyperglycemia ratio and in-hospital mortality in patients with coronary artery disease:insights from a large cohort study Cardiovasc Diabetol 2022 21 1 217 10.1186/s12933-022-01645-y 36261839
Xu W, Song Q, Wang X et al (2022) Association of stress hyperglycemia ratio and in-hospital mortality in patients with coronary artery disease:insights from a large cohort study. Cardiovasc Diabetol 21(1):217. 10.1186/s12933-022-01645-y36261839 10.1186/s12933-022-01645-y
26. Luo J Xu S Li H Prognostic impact of stress hyperglycemia ratio in acute myocardial infarction patients with and without diabetes mellitus Nutr Metab Cardiovasc Dis 2022 32 10 2356 2366 10.1016/j.numecd.2022.07.004 35965248
Luo J, Xu S, Li H et al (2022) Prognostic impact of stress hyperglycemia ratio in acute myocardial infarction patients with and without diabetes mellitus. Nutr Metab Cardiovasc Dis 32(10):2356–2366. 10.1016/j.numecd.2022.07.00435965248 10.1016/j.numecd.2022.07.004
27. Gao S Liu Q Chen H Predictive value of stress hyperglycemia ratio for the occurrence of acute kidney injury in acute myocardial infarction patients with diabetes BMC Cardiovasc Disord 2021 21 1 10 10.1186/s12872-021-01962-2 33388039
Gao S, Liu Q, Chen H et al (2021) Predictive value of stress hyperglycemia ratio for the occurrence of acute kidney injury in acute myocardial infarction patients with diabetes. BMC Cardiovasc Disord 21:1–10. 10.1186/s12872-021-01962-233388039 10.1186/s12872-021-01962-2
28. Zeng G Song Y Zhang Z Stress hyperglycemia ratio and long-term prognosis in patients with acute coronary syndrome: a multicenter, nationwide study J Diabetes 2023 15 7 557 568 10.1111/1753-0407.13400 37132473
Zeng G, Song Y, Zhang Z et al (2023) Stress hyperglycemia ratio and long-term prognosis in patients with acute coronary syndrome: a multicenter, nationwide study. J Diabetes 15(7):557–568. 10.1111/1753-0407.1340037132473 10.1111/1753-0407.13400
29. Liu B Chen Y Yu L Stress hyperglycemia ratio is associated with systemic inflammation and clinical outcomes in diabetic inpatients with pneumonia on admission J Diabetes 2023 15 7 545 556 10.1111/1753-0407.13398 37144245
Liu B, Chen Y, Yu L et al (2023) Stress hyperglycemia ratio is associated with systemic inflammation and clinical outcomes in diabetic inpatients with pneumonia on admission. J Diabetes 15(7):545–556. 10.1111/1753-0407.1339837144245 10.1111/1753-0407.13398
30. Tao J Hu Z Lou F Higher stress hyperglycemia ratio is associated with a higher risk of stroke-associated pneumonia Front Nutr 2022 9 784114 10.3389/fnut.2022.784114 35273985
Tao J, Hu Z, Lou F et al (2022) Higher stress hyperglycemia ratio is associated with a higher risk of stroke-associated pneumonia. Front Nutr 9:784114. 10.3389/fnut.2022.78411435273985 10.3389/fnut.2022.784114
31. Yang G Yan R Tong H Chronic oscillating glucose challenges disarrange innate immune homeostasis to potentiate the variation of neutrophil-lymphocyte ratio in rats with or without hidden diabetes mellitus Diabetes Metab Syndr Obes 2022 11 277 288 10.2147/DMSO.S160301
Yang G, Yan R, Tong H et al (2022) Chronic oscillating glucose challenges disarrange innate immune homeostasis to potentiate the variation of neutrophil-lymphocyte ratio in rats with or without hidden diabetes mellitus. Diabetes Metab Syndr Obes 11:277–288. 10.2147/DMSO.S16030110.2147/DMSO.S160301
32. Da Porto A Tascini C Colussi G Relationship between cytokine release and stress hyperglycemia in patients hospitalized with COVID-19 infection Front Med (Lausanne) 2022 9 988686 10.3389/fmed.2022.988686 36059840
Da Porto A, Tascini C, Colussi G et al (2022) Relationship between cytokine release and stress hyperglycemia in patients hospitalized with COVID-19 infection. Front Med (Lausanne) 9:988686. 10.3389/fmed.2022.98868636059840 10.3389/fmed.2022.988686
